返回 Agenda
Session 1 : Regulatory science perspective on Drug development using innovative tool
Session Chair(s)
Younglim Kim, PhD
Director General, National Institute of Food & Drug Safety (NIFDS), Korea, Republic of
Kyung Won Seo
Director General, National Institute of Food and Drug Safety Evaluation, Ministiry of Food and Drug Safety, Korea, Republic of
Speaker(s)
Meghana Chalasani, MHA
Associate Director for Clinical Trial Innovation, Office of New Drugs, CDER, FDA, United States
Susan M Sandler, RPh
Director, Global Regulatory Policy and Intelligence, Johnson & Johnson, United Kingdom
Session 1 - 2
Hironobu Saito, PhD
Corporate Advisor, Daiichi Sankyo Co., Ltd., Japan
Session 1 - 3
Sohee Kim, PhD
Executive Officer, Clinical Statistics Team, Yuhan Corporation , Korea, Republic of
Session 1 - 4
Junhee Pyo
Vice Chief, Convergence AI Institute for Drug Discovery, KPBMA, Korea, Republic of
Session 1 - 5
HaeSun Suh, PhD, MA, MPharm, RPh
Professor, College of Pharmacy, Kyung Hee University, Korea, Republic of
Minseok Kim
CBO, JNPMEDI, Korea, Republic of